WO2010122275A8 - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation Download PDF

Info

Publication number
WO2010122275A8
WO2010122275A8 PCT/GB2009/050415 GB2009050415W WO2010122275A8 WO 2010122275 A8 WO2010122275 A8 WO 2010122275A8 GB 2009050415 W GB2009050415 W GB 2009050415W WO 2010122275 A8 WO2010122275 A8 WO 2010122275A8
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
compositions
buccal
spray
treatment
Prior art date
Application number
PCT/GB2009/050415
Other languages
French (fr)
Other versions
WO2010122275A1 (en
Inventor
Calvin John Ross
Original Assignee
Londonpharma Ltd.
Ross, Elizabeth, Anita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Londonpharma Ltd., Ross, Elizabeth, Anita filed Critical Londonpharma Ltd.
Priority to PCT/GB2009/050415 priority Critical patent/WO2010122275A1/en
Priority to SG2011073954A priority patent/SG175162A1/en
Priority to RU2011139637/15A priority patent/RU2501550C2/en
Priority to BRPI1014887A priority patent/BRPI1014887A8/en
Priority to CN201080017965.1A priority patent/CN102395362B/en
Priority to MX2011010961A priority patent/MX2011010961A/en
Priority to MYPI2011005080A priority patent/MY155646A/en
Priority to US13/265,518 priority patent/US20120157518A1/en
Priority to CA2756925A priority patent/CA2756925A1/en
Priority to EP10715337A priority patent/EP2424523B1/en
Priority to PT10715337T priority patent/PT2424523E/en
Priority to NZ595469A priority patent/NZ595469A/en
Priority to JP2012506584A priority patent/JP5795760B2/en
Priority to MEP-2012-393A priority patent/ME02008B/en
Priority to DK10715337.1T priority patent/DK2424523T3/en
Priority to ES10715337T priority patent/ES2390046T3/en
Priority to PCT/GB2010/050672 priority patent/WO2010122356A1/en
Priority to RS20120393A priority patent/RS52430B/en
Priority to AU2010240654A priority patent/AU2010240654C1/en
Priority to SI201030076T priority patent/SI2424523T1/en
Priority to PL10715337T priority patent/PL2424523T3/en
Publication of WO2010122275A1 publication Critical patent/WO2010122275A1/en
Publication of WO2010122275A8 publication Critical patent/WO2010122275A8/en
Priority to ZA2011/07088A priority patent/ZA201107088B/en
Priority to IL215453A priority patent/IL215453A/en
Priority to HK12104912.3A priority patent/HK1164140A1/en
Priority to HRP20120711AT priority patent/HRP20120711T1/en
Priority to US14/813,424 priority patent/US20160022629A1/en
Priority to US15/697,240 priority patent/US20170368023A1/en
Priority to US16/164,610 priority patent/US20190142737A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides pharmaceutical compositions for the treatment of neoplastic diseases, fluke infestations and Lyme disease, comprising compounds capable of providing dihydroartemesinin and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.
PCT/GB2009/050415 2009-04-23 2009-04-23 Pharmaceutical preparation WO2010122275A1 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
PCT/GB2009/050415 WO2010122275A1 (en) 2009-04-23 2009-04-23 Pharmaceutical preparation
MEP-2012-393A ME02008B (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
PCT/GB2010/050672 WO2010122356A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
ES10715337T ES2390046T3 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
CN201080017965.1A CN102395362B (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
RU2011139637/15A RU2501550C2 (en) 2009-04-23 2010-04-23 Sublingual spray composition containing dihydroartemisinin
MYPI2011005080A MY155646A (en) 2009-04-23 2010-04-23 Pharmaceutical preparation
US13/265,518 US20120157518A1 (en) 2009-04-23 2010-04-23 Sublingual Spray Formulation Comprising Dihydroartemesinin
CA2756925A CA2756925A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
EP10715337A EP2424523B1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
PT10715337T PT2424523E (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
NZ595469A NZ595469A (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
RS20120393A RS52430B (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
SG2011073954A SG175162A1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
DK10715337.1T DK2424523T3 (en) 2009-04-23 2010-04-23 Sublingual spray formulation with dihydroartemisinin
BRPI1014887A BRPI1014887A8 (en) 2009-04-23 2010-04-23 pharmaceutical composition for use in treating neoplasms and use of a compound providing dihydroartemesinin via sublingual, transmucosal, buccal or nasal dosage
MX2011010961A MX2011010961A (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin.
JP2012506584A JP5795760B2 (en) 2009-04-23 2010-04-23 Sublingual spray formulation containing dihydroartemisinin
AU2010240654A AU2010240654C1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
SI201030076T SI2424523T1 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
PL10715337T PL2424523T3 (en) 2009-04-23 2010-04-23 Sublingual spray formulation comprising dihydroartemesinin
ZA2011/07088A ZA201107088B (en) 2009-04-23 2011-09-28 Sublingual spray formulation comprising dihydroartemesinin
IL215453A IL215453A (en) 2009-04-23 2011-10-02 Sublingual spray formulation comprising dihydroartemesinin
HK12104912.3A HK1164140A1 (en) 2009-04-23 2012-05-18 Sublingual spray formulation comprising dihydroartemesinin
HRP20120711AT HRP20120711T1 (en) 2009-04-23 2012-09-06 Sublingual spray formulation comprising dihydroartemesinin
US14/813,424 US20160022629A1 (en) 2009-04-23 2015-07-30 Sublingual Spray Formulation Comprising Dihydroartemesinin
US15/697,240 US20170368023A1 (en) 2009-04-23 2017-09-06 Sublingual spray formulation comprising dihydroartemesinin
US16/164,610 US20190142737A1 (en) 2009-04-23 2018-10-18 Sublingual spray formulation comprising dihydroartemesinin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/050415 WO2010122275A1 (en) 2009-04-23 2009-04-23 Pharmaceutical preparation

Publications (2)

Publication Number Publication Date
WO2010122275A1 WO2010122275A1 (en) 2010-10-28
WO2010122275A8 true WO2010122275A8 (en) 2010-12-23

Family

ID=41050376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/050415 WO2010122275A1 (en) 2009-04-23 2009-04-23 Pharmaceutical preparation

Country Status (1)

Country Link
WO (1) WO2010122275A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103223013A (en) * 2013-04-08 2013-07-31 张宗升 Traditional Chinese medicinal composition and its preparation method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623397B1 (en) * 1987-11-19 1993-08-13 Cosnier Alain MEDICINAL COMPOSITION BASED ON PLANTS FOR INTERNAL USE
CH692321A5 (en) * 1997-11-03 2002-05-15 Mepha Ag Pharmaceutically effective composition which comprises an effective anti-malarial parasite substance.

Also Published As

Publication number Publication date
WO2010122275A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2007048801A3 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2009014650A3 (en) Recombinant vibrio cholerae exotoxins
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
IL233677A (en) Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
IN2012DN02805A (en)
PH12013501567B1 (en) Anti-malarial pharmaceutical composition
WO2011082290A3 (en) Formulations from natural products, turmeric, and aspirin
AU2007295179A1 (en) Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2008043544A8 (en) Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
WO2011006143A3 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2010129918A8 (en) Triptolide prodrugs
WO2010138598A3 (en) Lxr modulators
WO2012106665A3 (en) Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
MY155646A (en) Pharmaceutical preparation
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
UA97401C2 (en) Improved taste-masking extrudates
WO2007009686A3 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2011069032A3 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09785216

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09785216

Country of ref document: EP

Kind code of ref document: A1